Nasdaq Drops 200 Points; American Woodmark Shares Spike Higher
U.S. stocks extended losses toward the end of trading, with the Nasdaq Composite dropping around 200 points on Tuesday
US Stocks Turn Lower; Dow Dips Over 200 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday
US Stock Futures Higher Ahead Of Economic Data, Fed Speakers
Pre-open movers
U.S. stock futures traded higher in early pre-market trade as investors digested comments from Federal Reserve Chairman Jerome Powell. Markets closed lower again on Monday, with the Nasdaq Composite dropping around 1% in the previous session.
US Stocks Pare Losses; Pinduoduo Shares Spike Higher
U.S. stocks pared losses toward the end of trading, with the Dow Jones dropping just 40 points on Monday.
Nasdaq Down Over 1%; Crude Oil Rises Sharply
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday.
OM Group Makes Hostile Takeover Bid For LSE 22 Years Ago Today
Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date.
What Happened?
On this day in 2000, Swedish company OM Group made a $1.2-billion hostile takeover bid for the London Stock Exchange.
Dow Falls Over 200 Points After Friday’s Plunge
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Monday.
Dow, Nasdaq Futures Lower Following Friday’s Sell-Off; US Dollar Surges To 20-Year High
Pre-open movers
U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled more than 1,000 points in the previous session following speech from Federal Reserve Chairman Jerome Powell at the central bank’s Jackson Hole economic symposium. The US dollar index, meanwhile, jumped to its strongest level in 20 years on Monday.
EU Antitrust Regulators Will Not Appeal EU Court Ruling Rejecting Its $991M Fine Against Qualcomm
-Reuters
https://www.reuters.com/technology/exclusive-eu-will-not-appeal-court-ruling-against-991-mln-qualcomm-fine-sources-2022-08-29/
Novartis Scemblix Approved by the European Commission for Adult Patients with Chronic Myeloid Leukemia
Novartis today announced that the European Commission (EC) has approved Scemblix® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)1.Novartis today announced that the European Commission (EC) has approved Scemblix® (asciminib) for th